logo
CDC nominee defends Kennedy shakeup of vaccine advisers

CDC nominee defends Kennedy shakeup of vaccine advisers

CNN5 hours ago

Vaccines
Federal agencies
Water availability
Congressional newsFacebookTweetLink
Follow
US Health and Human Services Secretary Robert F. Kennedy Jr.'s recent move to replace a federal panel of vaccine advisers should help restore Americans' trust in the US Centers for Disease Control and Prevention, the nominee to lead that agency told senators on Wednesday.
Dr. Susan Monarez, President Donald Trump's pick for CDC director, testified before the Senate Health, Education, Labor and Pensions Committee amid increasing alarm from lawmakers about Americans' eroding confidence in vaccine safety under Kennedy's leadership of HHS.
The Senate hearing happened the same morning that the CDC's newly appointed Advisory Committee on Immunization Practices convened its first meeting in Atlanta despite calls from lawmakers, including HELP Chairman Bill Cassidy, a Republican from Louisiana, to postpone the meeting.
'The secretary had to make a decision related to ensuring that the ACIP could be supportive of restoring public trust,' Monarez said when asked about the reassembled panel.
Kennedy dismissed all 17 ACIP members this month, citing conflicts of interest. Two days later, he named eight new members, several of whom had records of criticizing vaccine safety. As of Wednesday morning, one nominee, Dr. Michael Ross, had withdrawn during a federal review of members' financial holdings.
Monarez, a microbiologist and infectious disease expert who has served across several federal health agencies over the years, said she was not familiar with the details of the shakeup but would be open to placing more people on the committee. Although the CDC director can recommend experts to join ACIP, the HHS secretary ultimately signs off on appointments.
'These are not easy positions to fill,' Monarez said. 'It takes a lot of time commitment from some of these highly trained technical experts to want to participate.'
Cassidy and several Democratic senators sought reassurances from Monarez that she would protect ACIP's integrity as CDC director.
'Part of the concern is that the people on the panel, although scientifically credentialed, no one has the experience of [an] immunization [background] to say, 'Wait a second: The evidence that you're presenting, there's a lot more evidence to say it's not true.' That responsibility will fall on you,' Cassidy said, echoing concerns that he shared about the panel Monday and pointing to a specific presentation, slated for Thursday, on the preservative thimerosal in certain vaccines.
Cassidy also brought up mRNA, the technology in widely used Covid-19 vaccines that has early promise in other immunizations and potential therapies. Some vaccine critics, including new ACIP member Dr. Robert Malone, have touted unproven theories that mRNA vaccines can cause cancer and other serious side effects.
'If we turn our back on that platform, we're turning our back on solutions to Lyme disease, which is terribly debilitating, to HIV, which is a scourge,' Cassidy said. He pressed Monarez to include experts on the ACIP panel who have experience with mRNA and immunology.
She agreed.
'We absolutely need highly trained scientists and professionals to be able to participate,' Monarez said. ACIP 'is such a vital part of the CDC. It's such a vital, vital process.'
The nominee also said several times that 'vaccines save lives.'
At other points during the hearing, Monarez distanced herself from other Trump administration directives, including mass layoffs at the CDC and proposals to eliminate certain programs.
Monarez, who served as the CDC's deputy director from January to March and later as acting director, said repeatedly that she was not familiar with the details of layoffs that stalled lead poisoning prevention efforts or anti-tobacco education campaigns.
Monarez said she was not involved in personnel decisionmaking during those Department of Government Efficiency-led layoff, though she later said she worked with CDC staff to 'make sure we were reinforcing' the reduction in force plans.
Kennedy has been critical of the addition of fluoride to public water supplies, but Monarez was more noncommittal when questioned by Maryland Sen. Angela Alsobrooks, a Democrat, about the HHS secretary's plans to end CDC support of fluoridation in state and local drinking water.
'Fluoride is an important component to oral health,' Monarez said.
Alsobrooks noted that the public water supply in Potomac, Maryland, where Monarez lives, is fluoridated and asked Monarez whether it is safe.
'I believe the water in Potomac, Maryland, is safe,' Monarez replied.
Trump chose Monarez to lead the agency after withdrawing his first nominee, former Florida congressman Dr. Dave Weldon, from consideration. In a public letter after his withdrawal, Weldon accused Cassidy and Sen. Susan Collins of Maine of cratering his nomination amid concerns over his vaccine views.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oklahoma Supreme Court begins oral arguments on State Question 836
Oklahoma Supreme Court begins oral arguments on State Question 836

Yahoo

time24 minutes ago

  • Yahoo

Oklahoma Supreme Court begins oral arguments on State Question 836

OKLAHOMA CITY (KFOR) – Voters in Oklahoma could see a change in their voting process as oral deliberations begin in the Oklahoma Supreme Court regarding State Question 836. State Question 836 aims to reform the state's primary election system, allowing all registered voters, regardless of party affiliation, to participate in primary elections. Oklahoma Standard: Thunder celebration comes full circle 30 years after OKC bombing Currently, voters are only allowed to vote for their designated registered party, with Independents voting in Democratic primaries. Republicans are asking the Oklahoma Supreme Court to intervene, claiming open primaries could potentially spark confusion. Oklahoma Standard: Thunder celebration comes full circle 30 years after OKC bombing Supporters of SQ 836 are looking to score the Supreme Court's favor and begin gathering signatures for Oklahomans to vote on the matter. Tony Stobbe, a proponent for SQ 836, an independent voter and a retired U.S. Coast Guard Commander, witnessing the proceedings, says, 'This is not a partisan issue,' said Stobbe. 'Let the people vote. That's all we're asking. The only reason party insiders are trying to block SQ 836 in court is because they know it has real momentum. Oklahomans are ready for a system where every voter gets to vote in every election—and the political elites are clearly scared of that.' For more information or to support the campaign, visit This story is developing. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Oscar Health, Inc. (OSCR) Stock Moves -4.15%: What You Should Know
Oscar Health, Inc. (OSCR) Stock Moves -4.15%: What You Should Know

Yahoo

time36 minutes ago

  • Yahoo

Oscar Health, Inc. (OSCR) Stock Moves -4.15%: What You Should Know

Oscar Health, Inc. (OSCR) closed at $19.19 in the latest trading session, marking a -4.15% move from the prior day. Elsewhere, the Dow saw a downswing of 0.25%, while the tech-heavy Nasdaq appreciated by 0.31%. The company's shares have seen an increase of 33.38% over the last month, surpassing the Finance sector's gain of 3.26% and the S&P 500's gain of 5.05%. The investment community will be closely monitoring the performance of Oscar Health, Inc. in its forthcoming earnings report. The company is expected to report EPS of $0.34, up 70% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $2.86 billion, showing a 28.96% escalation compared to the year-ago quarter. OSCR's full-year Zacks Consensus Estimates are calling for earnings of $0.61 per share and revenue of $11.21 billion. These results would represent year-over-year changes of +510% and +22.12%, respectively. Investors should also note any recent changes to analyst estimates for Oscar Health, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 11.11% fall in the Zacks Consensus EPS estimate. Oscar Health, Inc. is holding a Zacks Rank of #3 (Hold) right now. Looking at valuation, Oscar Health, Inc. is presently trading at a Forward P/E ratio of 32.64. Its industry sports an average Forward P/E of 9.92, so one might conclude that Oscar Health, Inc. is trading at a premium comparatively. The Insurance - Multi line industry is part of the Finance sector. At present, this industry carries a Zacks Industry Rank of 70, placing it within the top 29% of over 250 industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Oscar Health, Inc. (OSCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Tenet Healthcare (THC) Stock Moves -1.46%: What You Should Know
Tenet Healthcare (THC) Stock Moves -1.46%: What You Should Know

Yahoo

time36 minutes ago

  • Yahoo

Tenet Healthcare (THC) Stock Moves -1.46%: What You Should Know

Tenet Healthcare (THC) closed at $169.01 in the latest trading session, marking a -1.46% move from the prior day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%. The stock of hospital operator has risen by 3.89% in the past month, leading the Medical sector's gain of 3.46% and undershooting the S&P 500's gain of 5.05%. The upcoming earnings release of Tenet Healthcare will be of great interest to investors. The company's earnings report is expected on July 22, 2025. The company is forecasted to report an EPS of $2.84, showcasing a 22.94% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $5.15 billion, indicating a 0.85% upward movement from the same quarter last year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $12.73 per share and revenue of $20.9 billion. These totals would mark changes of +7.15% and +1.12%, respectively, from last year. Investors should also take note of any recent adjustments to analyst estimates for Tenet Healthcare. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.33% higher within the past month. Tenet Healthcare is holding a Zacks Rank of #3 (Hold) right now. Valuation is also important, so investors should note that Tenet Healthcare has a Forward P/E ratio of 13.48 right now. This signifies a premium in comparison to the average Forward P/E of 11.25 for its industry. One should further note that THC currently holds a PEG ratio of 1.25. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. THC's industry had an average PEG ratio of 1.28 as of yesterday's close. The Medical - Hospital industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 96, which puts it in the top 40% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tenet Healthcare Corporation (THC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store